Visfatin mediates malignant transformation of endometrium in PCOS patients through PI3K-Akt and MAPK-ERK signaling pathways (17), which leads to a higher prevalence of endometrial cancer in PCOS patients compared to other women in reproductive age. This evidence concerns the gene NAMPT and polycystic ovary syndrome.